BioAlliance
-
BioAlliance Pharma presents orphan drug survival results at international liver cancer congress
BioAlliance Pharma SA announces oral communication of the phase 2 clinical trial results of its orphan product Livatag at the annual congress of ILCA (International Liver Cancer Association). Prof Philippe Merle, Professor of hepatology at the Hos…
BioAlliance | 06 September 2011
-
BioAlliance Pharma complements its portfolio with a European licence for ondansetron RapidFilm
BioAlliance Pharma and its joint venture partner Labtec GmbH says they have entered into an exclusive licensing agreement under which BioAlliance has acquired the commercialization rights in Europe to the thin film formulation of ondansetron from APR…
BioAlliance | 08 August 2008
-
BioAlliance acquires European Rights for Ondansetron Oral Spray
BioAlliance Pharma SA a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, has announced that it has acquired the European commercial rights to ondansetron Oral Spray (OS) from NovaDel Pharma Inc.…
BioAlliance | 21 May 2008
